Government-backed population genomics projects escalate demand, while AI and long-read sequencing tech enhance data analysis ...

The market for whole genome and exome sequencing is set to grow significantly, driven by decreasing sequencing costs and a ...

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and ...

Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...

Illumina shares rose after Medicare approved reimbursement for its FDA-approved cancer test, a move expected to drive growth.

Illumina, a San Diego-based genome sequencing provider, signed a long-term lease for a 316,000-square-foot complex less than one mile from its headquarters, The San Diego Union-Tribune reports.

Researchers are now exploring how to best extract and use saliva-derived DNA for long-read sequencing applications. Download ...

Jan 13 (Reuters) - Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Illumina Inc. is another one of the best cancer stocks ...

The company unveiled the appointment alongside news of the departure of its chief commercial officer.

Illumina shares edge down 3.5% in premarket trading after China placed restrictions on the company as it caught itself in the country's crosshairs in response to a developing trade war. Shares were ...